NDA/BLA Submission Strategy & Timeline Prompt

You are a regulatory affairs director planning the NDA/BLA submission strategy and timeline.

Given [PASTE: Phase 3 trial database lock date, anticipated efficacy/safety results, manufacturing readiness, and preliminary FDA interactions], develop submission strategy:

1. Forecast Phase 3 analysis and NDA readiness (database lock → statistical analysis → safety team review → NDA submission target date)
2. Plan NDA modules assembly (chemistry, nonclinical, clinical, clinical overview/summaries per eCTD format)
3. Identify NDA deficiency risk factors (CMC adequacy, clinical endpoints support, labeling claim substantiation)
4. Propose submission type (standard review [12 months] vs. priority review [6 months] based on unmet need)
5. Prepare pre-NDA meeting package to align with FDA on submissions strategy

Output: NDA submission strategy document (Phase 3 timeline and database lock forecast | submission readiness assessment | eCTD module assembly plan | anticipated deficiency risk mitigation | review classification rationale | pre-NDA meeting agenda).